Leo I Gordon

Feinberg School of Medicine, Feinberg Clinical, Medicine, Hematology Oncology Division

Scopus Publication Detail

The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in Scopus. This abstract is what is used to create the fingerprint of the publication.

Practical Considerations and Radiation Safety in Radioimmunotherapy with Yttrium 90 Ibritumomab Tiuxetan (Zevalin)

Leo I. Gordon (Profiled Author: Leo I Gordon)

Seminars in Oncology. 2003;30(6 SUPPL. 17):23-28.

⁹⁰Y ibritumomab tiuxetan (Zevalin; Biogen Idec Inc, Cambridge, MA), the first radioimmunotherapeutic agent approved by the US Food and Drug Administration, is a promising treatment option in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, including patients with rituximab-refractory follicular non-Hodgkin's lymphoma. The ibritumomab tiuxetan regimen is administered on an outpatient basis over approximately 1 week and with the simplicity of weight-based dosing (ie, calculation of whole body clearance is unnecessary). Other than acrylic shielding, only universal precautions are required to administer ⁹⁰Y ibritumomab tiuxetan, and patient isolation is unnecessary. This treatment regimen requires a coordinated multidisciplinary approach. Oncologists play a leading role in selecting patients for ⁹⁰Y ibritumomab tiuxetan therapy and in prescribing and overseeing the treatment. © 2003 Elsevier Inc. All rights reserved.

PMID: 14710400    

Scientific Context

This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.